IRIS
BUCCISANO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 44.969
EU - Europa 4.648
AS - Asia 2.262
SA - Sud America 50
AF - Africa 35
OC - Oceania 35
Continente sconosciuto - Info sul continente non disponibili 13
Totale 52.012
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 44.911
DE - Germania 1.219
SG - Singapore 980
IT - Italia 904
CN - Cina 735
UA - Ucraina 614
IE - Irlanda 538
RU - Federazione Russa 382
GB - Regno Unito 290
KR - Corea 232
FR - Francia 181
FI - Finlandia 153
SE - Svezia 143
IN - India 50
PL - Polonia 47
NL - Olanda 44
CA - Canada 41
ID - Indonesia 38
AU - Australia 31
BE - Belgio 29
IR - Iran 26
JP - Giappone 26
EG - Egitto 25
HK - Hong Kong 23
BR - Brasile 22
PH - Filippine 20
VN - Vietnam 20
AT - Austria 19
UZ - Uzbekistan 18
ES - Italia 16
MX - Messico 14
TR - Turchia 14
PE - Perù 13
PK - Pakistan 13
TH - Thailandia 13
CH - Svizzera 10
CZ - Repubblica Ceca 10
CL - Cile 9
EU - Europa 9
IQ - Iraq 9
TW - Taiwan 9
MY - Malesia 8
RO - Romania 8
SA - Arabia Saudita 8
PT - Portogallo 7
GR - Grecia 5
IL - Israele 5
RS - Serbia 5
A2 - ???statistics.table.value.countryCode.A2??? 4
AR - Argentina 4
NO - Norvegia 4
SK - Slovacchia (Repubblica Slovacca) 4
BD - Bangladesh 3
CR - Costa Rica 3
KG - Kirghizistan 3
LT - Lituania 3
NZ - Nuova Zelanda 3
BH - Bahrain 2
CO - Colombia 2
EE - Estonia 2
HR - Croazia 2
HU - Ungheria 2
MA - Marocco 2
NG - Nigeria 2
QA - Qatar 2
SD - Sudan 2
ZA - Sudafrica 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
DK - Danimarca 1
FJ - Figi 1
GE - Georgia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MM - Myanmar 1
PS - Palestinian Territory 1
SN - Senegal 1
TN - Tunisia 1
Totale 52.012
Salva come PNG Salva come JPEG
Città #
Woodbridge 13.566
Wilmington 11.985
Houston 9.181
Fairfield 1.533
Ann Arbor 1.086
Chandler 1.080
Singapore 866
Ashburn 864
Seattle 655
Jacksonville 535
Cambridge 531
Dublin 482
Dearborn 384
Medford 352
New York 340
Rome 310
Beijing 256
Santa Clara 223
Lawrence 164
Zhengzhou 152
Boardman 100
San Diego 82
Milan 77
Moscow 73
Menlo Park 60
Mülheim 59
Creede 51
Redwood City 46
Shanghai 46
Engelhard 44
London 41
Nanjing 40
Hefei 34
Jakarta 32
Bologna 29
Norwalk 29
Kraków 27
Munich 27
Brussels 26
Kunming 26
Center 25
Los Angeles 25
Seoul 25
Helsinki 24
University Park 24
Falls Church 22
Hangzhou 21
Palo Alto 21
Toronto 20
Guangzhou 17
Florence 16
Mountain View 16
Verona 16
Nürnberg 15
Pune 15
Dong Ket 14
Frankfurt am Main 13
Paris 13
Chicago 12
Council Bluffs 12
Nanchang 12
Bang Bai Mai 11
Chiswick 11
Lappeenranta 11
Lima 11
Saint Petersburg 11
Turin 11
Brno 10
Hackensack 10
Naples 10
Nuremberg 10
Fuzhou 9
Jinan 9
Kilburn 9
Manila 9
Detroit 8
Groningen 8
Hounslow 8
San Francisco 8
San Jose 8
Wuhan 8
Birmingham 7
Hebei 7
Innsbruck 7
Mumbai 7
Phoenix 7
Redmond 7
Roebling 7
Torre Del Greco 7
Warsaw 7
Washington 7
Alexandria 6
Cairo 6
Changsha 6
Kuala Lumpur 6
Latina 6
Monte Vista 6
Padova 6
Shenyang 6
Siena 6
Totale 46.186
Salva come PNG Salva come JPEG
Nome #
Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. 609
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 555
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 480
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): Phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial 470
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 469
An unusual endoscopic finding in a patient with melena: Multiple gastric ulcers of regular shape 458
Minimally differentiated acute myeloid leukemia (AML-MO): a distinct clinico-biologic entity with poor prognosis 455
Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia 452
AML-M0: A review of laboratory features and proposal of new diagnostic criteria 452
An allele-specific RT-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia 448
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 446
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes 444
Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. 440
Clinical significance of CD38 expression in chronic lymphocytic leukemia 437
CD7 expression in acute myeloid leukemia 437
Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr 435
Biological profile of 23 cases of minimally differentiated acute myeloid leukemia (AML-MO) and its clinical implications 432
Analysis of the expression of adhesion molecules on CD34+ progenitors from bone marrow, umbilical cord blood and G-CSF mobilized peripheral blood 430
Comparison between conventional banding analysis and FISH screening with an AML specific set of probes in 260 patients 429
Novel role of triazenes in haematological malignancies: Pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia 426
Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia 426
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) 425
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 425
A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias 424
Multiparametric analysis for the enumeration of CD34+ cells from bone marrow and stimulated peripheral blood 424
Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance 423
Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia 421
Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients 418
P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia 417
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 416
O6-(4-Bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro 415
Biological features of acute myeloid leukemia in the elderly 415
Cord blood transplantation in adults with acute myeloid leukaemia. 412
Minimally differentiated acute myeloid leukemia (AML-MO): Comparison of 25 cases with other French-American-British subtypes 411
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 411
P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia 406
Lecam1/Icam1 ratio identifies a distinct pattern on normal and myelodysplastic bone marrow CD34+ progenitors cells 405
Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia 405
AML-M0: a biological and clinical profile 402
SEQUENTIAL THERAPY WITH VAD, BORTEZOMIB AND CYCLOPHOSPHAMIDE AS INDUCTION THERAPY FOR MULTIPLE MYELOMA: A SEQUENTIAL PHARMACOLOGIC COMBINATION TO ACHIEVE COMPLETE REMISSIONS BEFORE STEM CELL TRANSPLANTATION 398
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes 396
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study 393
Minimally differentiated acute myeloid-leukemia (aml-mo): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases 391
Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia 388
Biological pattern of AML-M0 versus AML-M1: Response 386
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 386
Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia 384
Azacitidine for the treatment of patients with acute myeloid leukemia 383
Blood stem cell processing 382
Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage 382
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia 382
Cytogenetic and molecular diagnostic characterization combined to post-consolidation minimal residual disease assessment by flow-cytometry improves risk stratification in adult acute myeloid leukemia 381
P-glycoprotein expression in de novo acute myeloid leukemia 381
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation 380
Contribution of immunophenotypic and genotypic analysis to the diagnosis of acute leukemia 380
Quantitative analysis of P-glycoprotein, Bcl-2 and transferrin receptor allows the stratification of acute myeloid leukemia patients within different prognostic risk classes 378
Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia 378
Red blood cell depletion and cryopreservation of umbilical cord blood (UCB) 377
A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry 377
NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma 376
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR alpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study 375
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 375
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. 374
Mini-extracorporeal circulation minimizes coagulation abnormalities and ameliorates pulmonary outcome in coronary artery bypass grafting surgery 372
Minimally differentiated acute myeloid leukemia (AML-MO): A distinct clinico-biologic entity with poor prognosis 370
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study 368
Optimal post-remission therapy for flow-cytometry minimal residual disease positive adult patients with acute myeloid leukemia 366
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow 363
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. 361
Recombinant interferon alpha 2a, thymopentin and low doses of cytosine arabinoside for the treatment of myelodysplastic syndromes: a pilot study 361
A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy 361
All-trans retinoic acid and low dose cytosine arabinoside for the treatment of "poor prognosis" acute myeloid leukemia 360
The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia 358
Quantitative analysis of Fas and bcl-2 expression in hematopoietic precursors 358
Monitoring of minimal residual disease in acute myeloid leukemia 357
Thoracic cord compression caused by epidural extramedullary hematopoiesis during erythroid-stimulating agent therapy in two patients with myelodysplastic syndromes 357
Outcomes of allogeneic stem cell transplantation for secondary therapy-related acute myeloid leukaemia 357
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 355
Deferasirox chelation therapy in patients with transfusion-dependent MDS: A 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata 353
An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms 352
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications 352
High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma 351
Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia 349
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. 349
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database 348
Treatment of low-blast count AML using hypomethylating agents 348
Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients. 347
Reversible hyporegenerative anemia during natalizumab treatment 345
Extensive toxic epidermal necrolysis following brentuximab vedotin administration 344
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia 343
Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study 342
Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome 342
Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy 340
Treatment of Acute Myeloid Leukemia with 20-30% Bone Marrow Blasts 339
Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia 336
Minimal Residual Disease as Biomarker for Optimal Biologic Dosing of ARA-C in Patients with Acute Myeloid Leukemia 334
NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. 329
A cluster of Geotrichum clavatum (Saprochaete clavata) infection in haematological patients: a first Italian report and review of literature 328
Rituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia 327
Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia 326
Totale 39.236
Salva come PNG Salva come JPEG
Categoria #
all - tutte 114.068
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 114.068
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20207.501 0 0 0 0 0 1.411 1.247 1.109 1.055 1.076 733 870
2020/20217.478 840 865 745 1.008 769 713 951 711 229 219 328 100
2021/20221.970 66 193 81 67 54 194 131 129 167 177 136 575
2022/20232.915 285 232 218 295 198 569 331 188 331 51 161 56
2023/20241.656 137 48 197 49 136 502 78 112 40 47 43 267
2024/20252.185 172 978 519 278 111 127 0 0 0 0 0 0
Totale 52.686